<p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）的股票在 HC Wainwright 发布的一份报告中被维持 “买入” 评级，Benzinga 报道。该生物制药公司目前的目标股价为 8.00 美元。HC Wainwright 的目标价意味着该公司当前价格有 133.92% 的潜在上涨空间。</p>
<p>获取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
<ul>
<li>Akebia Therapeutics 因 FDA 批准贫血治疗而大幅上涨</li>
</ul>
<p>其他几家研究公司也对 AKBA 发表了看法。Jefferies Financial Group 在 4 月 1 日（星期二）的一份研究报告中开始覆盖 Akebia Therapeutics 的股票。他们给予该公司 “买入” 评级，目标价为 6.00 美元。Leerink Partners 在 4 月 28 日（星期一）的一份报告中将 Akebia Therapeutics 的评级上调至 “强力买入”。Piper Sandler 在 3 月 14 日（星期五）的一份研究报告中将 Akebia Therapeutics 的目标价从 4.00 美元上调至 6.00 美元，并给予该公司 “增持” 评级。Leerink Partners 在 4 月 28 日（星期一）的一份报告中开始覆盖 Akebia Therapeutics 的股票。他们设定了 “跑赢大盘” 的评级和 7.00 美元的目标价。最后，Wall Street Zen 在 5 月 3 日（星期六）的一份研究报告中将 Akebia Therapeutics 的评级从 “卖出” 上调至 “持有”。一位研究分析师对该股票给予了持有评级，四位分析师给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，平均目标价为 6.75 美元。</p>
<p><strong>查看我们关于 Akebia Therapeutics 的最新报告</strong></p>
<h2>Akebia Therapeutics 股票表现</h2>
<p>纳斯达克 AKBA 的股票在星期三开盘价为 3.42 美元。该公司的 50 日移动平均价格为 2.33 美元，200 日移动平均价格为 2.11 美元。Akebia Therapeutics 的 52 周低点为 0.80 美元，52 周高点为 3.49 美元。该公司的市值为 8.9822 亿美元，市盈率为-14.87，贝塔值为 0.88。</p>
<p>Akebia Therapeutics（纳斯达克：AKBA - 获取免费报告）最后一次公布财报是在 5 月 8 日（星期四）。该生物制药公司报告本季度每股收益为 0.03 美元，超出分析师一致预期的-0.03 美元 0.06 美元。该公司本季度的收入为 5734 万美元，而一致预期为 4488 万美元。分析师预测 Akebia Therapeutics 在当前年度的每股收益为-0.3 美元。</p>
<h2>Akebia Therapeutics 的机构交易</h2>
<p>对该公司的对冲基金最近对其持仓进行了调整。Vanguard Group Inc.在第一季度将其在 Akebia Therapeutics 的股份增加了 16.6%。Vanguard Group Inc.目前拥有 12685803 股该生物制药公司的股票，价值 24357000 美元，此前在上个季度购买了 1801603 股。Geode Capital Management LLC 在第四季度将其在 Akebia Therapeutics 的股份增加了 0.9%。Geode Capital Management LLC 目前拥有 4795095 股该生物制药公司的股票，价值 9112000 美元，此前在此期间购买了 40631 股。Renaissance Technologies LLC 在第四季度将其在 Akebia Therapeutics 的持股增加了 2.8%。Renaissance Technologies LLC 目前拥有 3823527 股该生物制药公司的股票，价值 7265000 美元，此前在上个季度购买了 105727 股。AIGH Capital Management LLC 在第一季度购买了 Akebia Therapeutics 的新股份，价值约 5616000 美元。最后，Goldman Sachs Group Inc.在第一季度将其在 Akebia Therapeutics 的持股增加了 171.8%。Goldman Sachs Group Inc.目前拥有 2724439 股该生物制药公司的股票，价值 5231000 美元，此前在上个季度购买了 1722245 股。当前 33.92% 的股票由机构投资者持有。</p>
<h2>关于 Akebia Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Akebia Therapeutics, Inc.是一家生物制药公司，专注于为肾脏疾病患者开发和商业化治疗方案。该公司的主要产品候选药物是 Vafseo（vadadustat），这是一种口服缺氧诱导因子脯氨酸羟化酶抑制剂，目前正在进行 III 期临床试验，旨在治疗因慢性肾病（CKD）导致的贫血，适用于依赖透析和不依赖透析的患者。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Akebia Therapeutics</li>
<li>在 52 周高点盈利交易股票</li>
<li>3 只分析师认为将上涨的便士股票</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>Constellation Energy 和 Meta 达成核能交易，股票剧烈波动</li>
<li>3 只引领迷因股票复苏的股票</li>
<li>特斯拉高达 200 的市盈率可能意味着更多上涨空间</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Akebia Therapeutics 吗？</h2>
<p>在考虑 Akebia Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Akebia Therapeutics 并不在名单上。</p>
<p>虽然 Akebia Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AKBA

<p>HC Wainwright 重申了对 Akebia Therapeutics（NASDAQ:AKBA）的 “买入” 评级，目标价为 8.00 美元，意味着潜在上涨空间为 133.92%。该股票目前交易价格为 3.42 美元，分析师的平均评级为 “买入”，目标价为 6.75 美元。Akebia 最近的财报显示每股盈利 0.03 美元，超出预期。机构投资者持有该股票的 33.92%，Vanguard Group 将其持股比例提高了 16.6%。Akebia 专注于开发肾脏疾病的治疗，特别是其主要候选药物 Vafseo，用于治疗慢性肾病引起的贫血</p>

<p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report)'s stock had its &#34;buy&#34; rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the biopharmaceutical company's stock. HC Wainwright's target price would indicate a potential upside of 133.92% from the company's current price.</p>
<div class="lb-trans"><p>Akebia Therapeutics（纳斯达克股票代码：AKBA - 获取免费报告）的股票在 HC Wainwright 发布的一份报告中被维持 “买入” 评级，Benzinga 报道。该生物制药公司目前的目标股价为 8.00 美元。HC Wainwright 的目标价意味着该公司当前价格有 133.92% 的潜在上涨空间。</p>
</div><p>Get <strong>Akebia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Akebia Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Akebia Therapeutics Surges on FDA Approval for Anemia Treatment</li>
</ul>
<div class="lb-trans"><ul>
<li>Akebia Therapeutics 因 FDA 批准贫血治疗而大幅上涨</li>
</ul>
</div><p>Several other research firms have also weighed in on AKBA. Jefferies Financial Group began coverage on shares of Akebia Therapeutics in a research note on Tuesday, April 1st. They issued a &#34;buy&#34; rating and a $6.00 price objective for the company. Leerink Partnrs upgraded Akebia Therapeutics to a &#34;strong-buy&#34; rating in a report on Monday, April 28th. Piper Sandler boosted their price target on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, March 14th. Leerink Partners began coverage on shares of Akebia Therapeutics in a report on Monday, April 28th. They set an &#34;outperform&#34; rating and a $7.00 price objective on the stock. Finally, Wall Street Zen upgraded Akebia Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, May 3rd. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of &#34;Buy&#34; and an average price target of $6.75.</p>
<div class="lb-trans"><p>其他几家研究公司也对 AKBA 发表了看法。Jefferies Financial Group 在 4 月 1 日（星期二）的一份研究报告中开始覆盖 Akebia Therapeutics 的股票。他们给予该公司 “买入” 评级，目标价为 6.00 美元。Leerink Partners 在 4 月 28 日（星期一）的一份报告中将 Akebia Therapeutics 的评级上调至 “强力买入”。Piper Sandler 在 3 月 14 日（星期五）的一份研究报告中将 Akebia Therapeutics 的目标价从 4.00 美元上调至 6.00 美元，并给予该公司 “增持” 评级。Leerink Partners 在 4 月 28 日（星期一）的一份报告中开始覆盖 Akebia Therapeutics 的股票。他们设定了 “跑赢大盘” 的评级和 7.00 美元的目标价。最后，Wall Street Zen 在 5 月 3 日（星期六）的一份研究报告中将 Akebia Therapeutics 的评级从 “卖出” 上调至 “持有”。一位研究分析师对该股票给予了持有评级，四位分析师给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat 的数据，该股票的平均评级为 “买入”，平均目标价为 6.75 美元。</p>
</div><p><strong>Check Out Our Latest Report on Akebia Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Akebia Therapeutics 的最新报告</strong></p>
</div><h2>Akebia Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 股票表现</h2>
</div><p>Shares of NASDAQ AKBA opened at $3.42 on Wednesday. The company's 50 day moving average price is $2.33 and its 200-day moving average price is $2.11. Akebia Therapeutics has a 52-week low of $0.80 and a 52-week high of $3.49. The company has a market capitalization of $898.22 million, a P/E ratio of -14.87 and a beta of 0.88.</p>
<div class="lb-trans"><p>纳斯达克 AKBA 的股票在星期三开盘价为 3.42 美元。该公司的 50 日移动平均价格为 2.33 美元，200 日移动平均价格为 2.11 美元。Akebia Therapeutics 的 52 周低点为 0.80 美元，52 周高点为 3.49 美元。该公司的市值为 8.9822 亿美元，市盈率为-14.87，贝塔值为 0.88。</p>
</div><p>Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.06. The firm had revenue of $57.34 million for the quarter, compared to the consensus estimate of $44.88 million. Analysts forecast that Akebia Therapeutics will post -0.3 earnings per share for the current year.</p>
<div class="lb-trans"><p>Akebia Therapeutics（纳斯达克：AKBA - 获取免费报告）最后一次公布财报是在 5 月 8 日（星期四）。该生物制药公司报告本季度每股收益为 0.03 美元，超出分析师一致预期的-0.03 美元 0.06 美元。该公司本季度的收入为 5734 万美元，而一致预期为 4488 万美元。分析师预测 Akebia Therapeutics 在当前年度的每股收益为-0.3 美元。</p>
</div><h2>Institutional Trading of Akebia Therapeutics</h2>
<div class="lb-trans"><h2>Akebia Therapeutics 的机构交易</h2>
</div><p>Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Akebia Therapeutics by 16.6% in the first quarter. Vanguard Group Inc. now owns 12,685,803 shares of the biopharmaceutical company's stock worth $24,357,000 after purchasing an additional 1,801,603 shares in the last quarter. Geode Capital Management LLC boosted its stake in Akebia Therapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,795,095 shares of the biopharmaceutical company's stock worth $9,112,000 after purchasing an additional 40,631 shares during the period. Renaissance Technologies LLC grew its holdings in Akebia Therapeutics by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,823,527 shares of the biopharmaceutical company's stock valued at $7,265,000 after buying an additional 105,727 shares in the last quarter. AIGH Capital Management LLC bought a new stake in shares of Akebia Therapeutics during the first quarter valued at about $5,616,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Akebia Therapeutics by 171.8% in the first quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company's stock worth $5,231,000 after buying an additional 1,722,245 shares in the last quarter. 33.92% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对该公司的对冲基金最近对其持仓进行了调整。Vanguard Group Inc.在第一季度将其在 Akebia Therapeutics 的股份增加了 16.6%。Vanguard Group Inc.目前拥有 12685803 股该生物制药公司的股票，价值 24357000 美元，此前在上个季度购买了 1801603 股。Geode Capital Management LLC 在第四季度将其在 Akebia Therapeutics 的股份增加了 0.9%。Geode Capital Management LLC 目前拥有 4795095 股该生物制药公司的股票，价值 9112000 美元，此前在此期间购买了 40631 股。Renaissance Technologies LLC 在第四季度将其在 Akebia Therapeutics 的持股增加了 2.8%。Renaissance Technologies LLC 目前拥有 3823527 股该生物制药公司的股票，价值 7265000 美元，此前在上个季度购买了 105727 股。AIGH Capital Management LLC 在第一季度购买了 Akebia Therapeutics 的新股份，价值约 5616000 美元。最后，Goldman Sachs Group Inc.在第一季度将其在 Akebia Therapeutics 的持股增加了 171.8%。Goldman Sachs Group Inc.目前拥有 2724439 股该生物制药公司的股票，价值 5231000 美元，此前在上个季度购买了 1722245 股。当前 33.92% 的股票由机构投资者持有。</p>
</div><h2>About Akebia Therapeutics</h2>
<div class="lb-trans"><h2>关于 Akebia Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.</p>
<div class="lb-trans"><p>Akebia Therapeutics, Inc.是一家生物制药公司，专注于为肾脏疾病患者开发和商业化治疗方案。该公司的主要产品候选药物是 Vafseo（vadadustat），这是一种口服缺氧诱导因子脯氨酸羟化酶抑制剂，目前正在进行 III 期临床试验，旨在治疗因慢性肾病（CKD）导致的贫血，适用于依赖透析和不依赖透析的患者。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Akebia Therapeutics</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>3 Penny Stocks Analysts Believe Are Headed Higher</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Tesla’s Lofty 200 P/E Could Mean More Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Akebia Therapeutics</li>
<li>在 52 周高点盈利交易股票</li>
<li>3 只分析师认为将上涨的便士股票</li>
<li>突破股票：它们是什么以及如何识别它们</li>
<li>Constellation Energy 和 Meta 达成核能交易，股票剧烈波动</li>
<li>3 只引领迷因股票复苏的股票</li>
<li>特斯拉高达 200 的市盈率可能意味着更多上涨空间</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUtCQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=AKBA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Akebia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Akebia Therapeutics 吗？</h2>
</div><p>Before you consider Akebia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Akebia Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Akebia Therapeutics 并不在名单上。</p>
</div><p>While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Akebia Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Akebia Therapeutics（纳斯达克代码：AKBA）被 HC Wainwright 给予买入评级